Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study

Findings from the iNTEGRATE trial comparing ibrutinib-prednisone and placebo-prednisone arms showed no statistical difference in the following end points: response rates at 48 weeks (41% vs. 37%, respectively), median event free survival (15 vs. 8 months) and improvement in overall Lee chronic GVHD Symptom Scale (43% vs 31%). Grade 3 or greater serious adverse events were similar in both arms (49% vs. 47% in the placebo arm).